Huntington Disease

In a symptomatic patient, obtain a three-generation pedigree and document progressive motor, cognitive, and psychiatric findings. Huntington disease is an autosomal dominant disorder caused by a CAG-repeat expansion in HTT on chromosome 4; the classic clinical syndrome combines progressive motor dysfunction, cognitive decline, and psychiatric disturbance. ScienceDirectScienceDirectBiological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

Order targeted HTT CAG-repeat analysis when the clinical phenotype is compatible with Huntington disease, particularly with an affected parent or other convincing family history. A repeat length of 36 or more is described as disease-causing; in a symptomatic person, molecular confirmation resolves diagnostic uncertainty created by variable psychiatric, cognitive, and motor presentation. ScienceDirectScienceDirectBiological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

Do not equate a positive molecular result with a motor diagnosis in an asymptomatic carrier. Formal clinical diagnosis has traditionally relied on diagnostic motor signs in a person with a positive family history, confirmed by gene testing; a mutation carrier without diagnostic motor signs should be managed as premanifest rather than assigned symptomatic disease solely from genotype. ScienceDirectScienceDirectBiological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

For a patient with new or subacute chorea, first review medication exposure and evaluate for general internal or iatrogenic causes before attributing the syndrome to Huntington disease. The recognized differential includes general internal disorders, drug-induced chorea, and inherited Huntington disease phenocopies. ScienceDirectScienceDirectBiological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

A negative HTT result in a patient with a Huntington-like syndrome changes the next action: document the exact motor phenotype, cognitive profile, psychiatric syndrome, and family structure; obtain focused neurogenetic assessment rather than repeating HTT testing without a laboratory reason. Phenocopies are observed among clinically diagnosed cases lacking the HTT mutation. JAMA+1JAMAHuntington DiseaseScienceDirectBiological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

Use CAG repeat length as a prognostic modifier, not a stand-alone forecast for an individual patient. Repeat length correlates with age at onset, but genetic modifiers also influence clinical onset and progression; DNA-maintenance loci have been identified as modifiers in genome-wide studies. cell+3cellGenetic modifiers of Huntington disease differentially ...cellIdentification of Genetic Factors that Modify Clinical Onset ...cellGenetic Modification of Huntington Disease Acts Early in ...WileyGenetic Testing of HTT Modifiers for Huntington's Disease ...

Offer predictive HTT testing only to an at-risk adult who requests to know carrier status and completes a multidisciplinary pretest process. Predictive testing can identify expanded-repeat carriers before symptom onset, but premanifest diagnosis should be conducted by multidisciplinary teams rather than treated as a simple screening assay. ScienceDirectScienceDirectBiological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

Before blood draw, establish the patient’s reason for testing, readiness to receive either result, psychiatric history, available support person, planned method of disclosure, and immediate post-result contact plan. Contemporary predictive-testing frameworks emphasize structured pretest counseling and mental-health considerations; family-system implications are particularly relevant for candidates at 25% risk. Wiley+1WileyPredictive Genetic Testing: The Huntington Disease ModelWiley40+ years of the Huntington disease predictive genetic ...

For reproductive decisions, explain that an intermediate allele of 27-35 repeats does not cause Huntington disease in the carrier but can expand in subsequent generations. Discuss referral to reproductive genetics when an expanded allele or intermediate allele creates concern about transmission; prenatal diagnosis using chorionic villus sampling is described as an available option. ScienceDirect+1ScienceDirectBiological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline dataScienceDirectHuntington Disease Like Syndrome - an overview

Treat chorea when it interferes with activities, causes injury, or materially burdens the patient or caregiver. Up to 90% of affected patients may develop chorea; tetrabenazine is FDA-indicated for Huntington chorea, and deutetrabenazine was FDA-approved for Huntington chorea in 2017. fda+2fdaHuntington's DiseaseJAMASafety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of ChoreaPubMedReview of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease - PMC

Select a vesicular monoamine transporter 2 inhibitor after screening for depression, suicidal thoughts, and suicidal behavior. Tetrabenazine has serious warnings for depression and suicidality; this risk is particularly consequential because psychiatric symptoms can be among the most difficult manifestations of Huntington disease for patients and caregivers. fdafdaHuntington's Disease

Deutetrabenazine is a reasonable alternative when twice-daily administration and lower plasma fluctuation are advantageous. In FIRST-HD, deutetrabenazine improved chorea and motor outcomes versus placebo; its deuterated pharmacokinetic profile permits lower peak concentrations and reduced fluctuations than tetrabenazine, although no head-to-head randomized trial has established comparative efficacy between the two agents. JAMA+2JAMASafety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of ChoreaWileyPharmacokinetics of Deutetrabenazine and Tetrabenazine ...PubMedReview of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease - PMC

A patient receiving stable, beneficial tetrabenazine can be converted overnight to deutetrabenazine under an appropriate conversion plan; an open-label study evaluated overnight switching in 37 patients. Use clinical follow-up to reassess chorea benefit, mood, behavior, sleep, and functional impact after conversion rather than assuming pharmacologic equivalence in every patient. JAMAJAMASafety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea

At follow-up, reassess motor function, cognition, psychiatric symptoms, weight and intake, speech and swallowing, falls, caregiver burden, and practical supports. Huntington disease remains progressive despite available symptomatic therapies, and current treatments reduce symptom impact without adequately controlling worsening across disease progression. fda+1fdaHuntington's DiseaseNatureHuntington disease | Nature Reviews Disease Primers

Use a multidisciplinary clinic model when available because motor, psychiatric, cognitive, nutritional, communication, and family needs commonly coexist. For juvenile Huntington disease, multidisciplinary symptomatic and supportive management is particularly emphasized because developmental, educational, and caregiver decisions accompany progressive neurologic disease. fda+1fdaHuntington's DiseaseOxford Academic4 Juvenile Huntington's Disease - Oxford Academic

Discuss clinical-trial referral with interested patients and families, particularly at specialized Huntington disease centers. Targeted huntingtin-lowering approaches and biomarkers have been major areas of therapeutic development, but they should be presented as investigational rather than disease-modifying standard care. fda+2fdaChristopher S. CoffeyNatureHuntington disease | Nature Reviews Disease PrimersNatureHuntington disease: natural history, biomarkers and prospects for therapeutics | Nature Reviews Neurology

Do not offer modifier-gene testing or experimental huntingtin-lowering therapy as routine clinical management. Genetic studies indicate that pathogenesis may be modifiable before clinical diagnosis and that modifier loci act early, but this does not establish a current individual-level treatment indication. cell+2cellIdentification of Genetic Factors that Modify Clinical Onset ...cellGenetic Modification of Huntington Disease Acts Early in ...WileyGenetic Testing of HTT Modifiers for Huntington's Disease ...